Skip to main content
Equibles
ISPC logo

ISPC · iSpecimen Inc. · Metrics

Track ISPC — free

Use ISPC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ISPC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.68 -0.01 (-2.05%) Q4 2023 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued. Management's plan to mitigate the conditions that raise substantial doubt includes generating additional revenues, deferring certain projects and capital expenditures and eliminating certain future operating expenses for the Company to continue as a going concern. However, there can be no assurance that the Company will be successful in completing any of these options. As a result, management's plans cannot be considered probable and thus do not alleviate substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.75M
Shares
2.52M
Volume · Nov 12 30.37K Avg daily vol (3M) 721.62K

ISPC metrics

60 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.70
Market cap
$1.75M

Price action

23 metrics
Price change (1W)
-15.8%
Price change (30D)
-34.3%
Price change (3M)
-68.7%
Price change (6M)
-83.1%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
89.0%
Annualized volatility (3M)
79.0%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.4
RSI (14D)
27.8
Price vs SMA 50
-35.7%
Price vs SMA 200
—
Avg volume (3M)
721,903
Relative volume
0.1
Average dollar volume
$1.11M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
2.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.8×
reciprocal yield 26.1%
P / book
1.0
reciprocal yield 97.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-639.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.7×
reciprocal yield 140.3%
EV / revenue historical average (5Y)
0.4×
reciprocal yield 278.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-08-06

Profitability

9 metrics
Gross margin
-67.2%
Operating margin
-2,020.0%
Trailing 12 months
Net margin
-2,449.0%
Gross profit (TTM)
−$313,275
Operating profit (TTM)
−$9.42M
Net income (TTM)
−$11.42M
Trailing 12 months
Diluted EPS (TTM)
$-53.51
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$14.57

Growth

11 metrics
Revenue growth YoY
-78.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$466,302
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,133.9%
Year over year · more shares
Revenue CAGR (3Y)
-43.0%
Revenue CAGR (5Y)
-25.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-657.7%
Return on assets
-154.5%
Debt / equity
0.0
Current ratio
0.8
EBITDA (TTM)
−$8.22M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.41M
Latest balance sheet
Cash & equivalents
$4.41M
Total assets
$7.39M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.00M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$4,743
R&D / revenue
—
Stock compensation / revenue
1.0%

Ownership (13F)

9 metrics
13F filers
8
13F filer change QoQ
-4
Institutional ownership
2.6%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+1,293.3%
Holder tenure
3.4
Price vs estimated holder cost
-99.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
12.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1558569 CUSIP 45032V306 13F (30d) 6 filings 6 filers Visit website Investor relations